+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

North America Hyperphosphatemia Drugs Market 2019-2027

  • ID: 4791836
  • Report
  • Region: North America, United States
  • 71 pages
  • Triton Market Research
1 of 3

FEATURED COMPANIES

  • Amag Pharmaceuticals
  • Bruno Farmaceutici S.P.A.
  • Fermenta Biotech, Ltd.
  • Johnson and Johnson
  • Royal Dsm N.V.
  • Shire
  • MORE
Market Outlook

This research has concluded that the North America hyperphosphatemia drugs market is projected to grow at a CAGR of 15.66% in the estimated years 2019-2027.

Canada and the United States together form the hyperphosphatemia drugs market in the North America region.

The growing elderly population is a major driving factor for the growth of the hyperphosphatemia drugs market in Canada. The number of elderly citizens in the general population is progressively growing in the country. As the elderly population in Canada increases, the number of diseases such as hypertension, osteoporosis, etc., in them will also increase. Chronic kidney disease (CKD) is a significant public health issue. CKD is a crucial risk multiplier in patients with heart disease, diabetes, stroke and hypertension. Subsequently, the prevalence of CKD is quite high in elder citizens in Canada. Kidney disease can be described as a variety of diseases and disorders that affect the kidneys. Most of the diseases related to kidney affect the nephrons, which are the kidneys’ filtering units—and retard their ability of eliminating excess fluids and wastes. In the case of chronic kidney disease, an increase in the blood’s phosphorus levels occur due to improper excretions leading to hyperphosphatemia. Increasing cases for hyperphosphatemia in the elderly population is one of the most significant reasons contributing to the growth of the country’s hyperphosphatemia drugs market.

Competitive Outlook

The biggest brands in the hyperphosphatemia drugs market include Sun Pharmaceutical Industries, Ltd., Shire, Cipla, Fresenius Medical Care, Fermenta Biotech, Ltd., Royal DSM N.V., Ultragenyx Pharmaceutical, Inc., Bio-Tech Pharmacal, Johnson and Johnson, Bruno Farmaceutici S.p.A., Keryx Biopharmaceuticals, Inc., Zeria Pharmaceutical, AMAG Pharmaceuticals, Roche Diagnostics Corporation, Sanofi and Pfizer, Inc.

Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Amag Pharmaceuticals
  • Bruno Farmaceutici S.P.A.
  • Fermenta Biotech, Ltd.
  • Johnson and Johnson
  • Royal Dsm N.V.
  • Shire
  • MORE
1. North America Hyperphosphatemia Drugs Market - Summary

2. Industry Outlook
2.1. Market Definition
2.2. Porter’s Five Force Model
2.2.1. Threat of New Entrants
2.2.2. Bargaining Power of Buyers
2.2.3. Bargaining Power of Suppliers
2.2.4. Threat of Substitute Product
2.2.5. Intensity of Competitive Rivalry
2.3. Vendor Scorecard
2.4. Key Buying Outlook
2.5. Key Insights
2.6. Key Market Trends
2.7. Guidelines Related to the Phosphate Binders
2.8. Market Drivers
2.8.1. Chronic Disorders are Increasing Rapidly
2.8.2. Increase in Public Cognizance
2.8.3. Increase in Geriatric Population
2.9. Market Restraints
2.9.1. Side-Effects Related to the Usage of Hyperphosphatemia Drugs
2.9.2. Strict Food and Drug Administration (Fda) Regulations
2.10. Market Opportunities
2.10.1. Rise in the Aging Population
2.11. Market Challenges
2.11.1. Alternative Dialysis Techniques
2.11.2. Accessibility of Drugs is Limited
2.11.3. Non-Adherence to Treatment Regimes

3. Hyperphosphatemia Drugs Market Outlook - By Dosages
3.1. Solid
3.1.1. Tablet
3.1.2. Powder
3.2. Liquid
3.2.1. Solution

4. Hyperphosphatemia Drugs Market Outlook - By Formulation
4.1.1. Calcium-Based Phosphate Binders
4.1.2. Aluminum-Based Phosphate Binders
4.1.3. Magnesium-Based Phosphate Binders
4.1.4. Iron-Based Phosphate Binders
4.1.5. Other Phosphate Binders

5. Hyperphosphatemia Drugs Market - Regional Outlook
5.1. North America
5.1.1. Country Analysis
5.1.1.1. The United States
5.1.1.2. Canada

6. Competitive Landscape
6.1. Johnson and Johnson
6.2. Zeria Pharmaceutical
6.3. Amag Pharmaceuticals
6.4. Sanofi
6.5. Bruno Farmaceutici S.P.A.
6.6. Roche Diagnostics Corporation
6.7. Royal Dsm N.V.
6.8. Shire
6.9. Cipla
6.10. Ultragenyx Pharmaceutical, Inc.
6.11. Fermenta Biotech, Ltd.
6.12. Biotech Pharmacal
6.13. Sun Pharmaceutical Industries, Ltd.
6.14. Keryx Biopharmaceuticals, Inc.
6.15. Fresenius Medical Care
6.16. Pfizer, Inc.

7. Methodology & Scope
7.1. Research Scope
7.2. Sources of Data
7.3. Research Methodology

List of Tables
Table 1 North America Hyperphosphatemia Drugs Market 2019-2027 ($ Million)
Table 2 Phosphorous Levels in Select Foods
Table 3 North America Hyperphosphatemia Drugs Market By Formulation 2019-2027 ($ Million)
Table 4 Diagnosis and Clinical Indicators of Chronic Kidney Disease
Table 5 North America Hyperphosphatemia Drugs Market Country Analysis 2019-2027 ($ Million)

List of Figures
Figure 1 Porter’s Five Forces Model of Hyperphosphatemia Drugs Market
Figure 2 Iron-Based Hyperphosphatemia Drug Approval Status 2014-2017
Figure 3 Rate of Adherence to Phosphate Binders
Figure 4 North America Hyperphosphatemia Drugs Market in Calcium-Based Phosphate Binders 2019-2027 ($ Million)
Figure 5 North America Hyperphosphatemia Drugs Market in Aluminum-Based Phosphate Binders 2019-2027 ($ Million)
Figure 6 North America Hyperphosphatemia Drugs Market in Magnesium-Based Phosphate Binders 2019-2027 ($ Million)
Figure 7 North America Hyperphosphatemia Drugs Market in Iron-Based Phosphate Binders 2019-2027 ($ Million)
Figure 8 North America Hyperphosphatemia Drugs Market in Other Phosphate Binders 2019-2027 ($ Million)
Figure 9 North America Hyperphosphatemia Drugs Market Share 2018 & 2027 (%)
Figure 10 North America Hyperphosphatemia Drugs Market 2019-2027 ($ Million)
Figure 11 United States Hyperphosphatemia Drugs Market 2019-2027 ($ Million)
Figure 12 Canada Hyperphosphatemia Drugs Market 2019-2027 ($ Million)
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Johnson and Johnson
  • Zeria Pharmaceutical
  • Amag Pharmaceuticals
  • Sanofi
  • Bruno Farmaceutici S.P.A.
  • Roche Diagnostics Corporation
  • Royal Dsm N.V.
  • Shire
  • Cipla
  • Ultragenyx Pharmaceutical, Inc.
  • Fermenta Biotech, Ltd.
  • Biotech Pharmacal
  • Sun Pharmaceutical Industries, Ltd.
  • Keryx Biopharmaceuticals, Inc.
  • Fresenius Medical Care
  • Pfizer, Inc.
Note: Product cover images may vary from those shown
Adroll
adroll